JP5990106B2 - 縮環化合物 - Google Patents

縮環化合物 Download PDF

Info

Publication number
JP5990106B2
JP5990106B2 JP2012554878A JP2012554878A JP5990106B2 JP 5990106 B2 JP5990106 B2 JP 5990106B2 JP 2012554878 A JP2012554878 A JP 2012554878A JP 2012554878 A JP2012554878 A JP 2012554878A JP 5990106 B2 JP5990106 B2 JP 5990106B2
Authority
JP
Japan
Prior art keywords
group
compound
methyl
formula
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012554878A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012102405A1 (ja
Inventor
啓太 永井
啓太 永井
考 長澤
考 長澤
高橋　博文
博文 高橋
基彰 馬場
基彰 馬場
真一 藤岡
真一 藤岡
江里 近藤
江里 近藤
田中　健一
健一 田中
良樹 伊藤
良樹 伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sato Pharmaceutical Co Ltd
Original Assignee
Sato Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sato Pharmaceutical Co Ltd filed Critical Sato Pharmaceutical Co Ltd
Publication of JPWO2012102405A1 publication Critical patent/JPWO2012102405A1/ja
Application granted granted Critical
Publication of JP5990106B2 publication Critical patent/JP5990106B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2012554878A 2011-01-28 2012-01-30 縮環化合物 Expired - Fee Related JP5990106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011016950 2011-01-28
JP2011016950 2011-01-28
PCT/JP2012/052009 WO2012102405A1 (ja) 2011-01-28 2012-01-30 縮環化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016158397A Division JP6223514B2 (ja) 2011-01-28 2016-08-12 縮環化合物

Publications (2)

Publication Number Publication Date
JPWO2012102405A1 JPWO2012102405A1 (ja) 2014-07-03
JP5990106B2 true JP5990106B2 (ja) 2016-09-07

Family

ID=46580968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012554878A Expired - Fee Related JP5990106B2 (ja) 2011-01-28 2012-01-30 縮環化合物
JP2016158397A Expired - Fee Related JP6223514B2 (ja) 2011-01-28 2016-08-12 縮環化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016158397A Expired - Fee Related JP6223514B2 (ja) 2011-01-28 2016-08-12 縮環化合物

Country Status (5)

Country Link
US (2) US8987473B2 (enExample)
EP (1) EP2669270B1 (enExample)
JP (2) JP5990106B2 (enExample)
DK (1) DK2669270T3 (enExample)
WO (1) WO2012102405A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567328B2 (en) 2011-12-21 2017-02-14 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
DK2878594T3 (en) * 2012-07-27 2019-02-04 Sato Pharma DIFLUOROMETHYLENE COMPOUND
CN102875590A (zh) * 2012-10-22 2013-01-16 北京林业大学 芳香族三丁基锡衍生物的制备方法
JP6449482B2 (ja) 2015-03-24 2019-01-09 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用
KR102708936B1 (ko) 2015-11-20 2024-09-25 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 억제제로서의 퓨리논
CN106045898B (zh) * 2016-06-28 2019-05-24 广东东阳光药业有限公司 一种吲哚类化合物及其制备方法和用途
CN106146533B (zh) * 2016-07-14 2018-04-03 华润赛科药业有限责任公司 含硫杂环羧酸类衍生物、其制备方法和应用
EP3538151B1 (en) 2016-11-11 2024-06-26 Whitehead Institute for Biomedical Research Human plasma-like medium
TWI774755B (zh) 2017-04-28 2022-08-21 日商佐藤製藥股份有限公司 二氟甲烯化合物之製造法
US10934294B2 (en) 2017-06-08 2021-03-02 Merck Sharp & Dohme Corp. Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors
JP2020524718A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
CA3143105A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
CN114007691A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 吡啶氨基甲酸酯及其作为GluN2B受体调节剂的用途
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
CA3143276A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
CN113993868A (zh) * 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途
WO2022076975A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
TWI870839B (zh) * 2022-04-27 2025-01-21 大陸商杭州新元素藥業有限公司 可用於降尿酸的化合物

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05222000A (ja) * 1991-10-14 1993-08-31 Fujisawa Pharmaceut Co Ltd ベンズイミダゾール誘導体およびその製造方法
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO1998005327A1 (en) * 1996-08-05 1998-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
JPH10503488A (ja) * 1994-11-25 1998-03-31 三共株式会社 複素環化合物、その製造及びその治療的用途
WO1998015530A1 (en) * 1996-10-08 1998-04-16 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
WO1999000372A1 (fr) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfamides et leur utilisation medicale
WO1999000373A1 (en) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
JPH11503445A (ja) * 1995-04-10 1999-03-26 藤沢薬品工業株式会社 ｃＧＭＰ−ＰＤＥ阻害剤としてのインドール誘導体
WO2000039099A1 (en) * 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US20020143022A1 (en) * 1998-01-14 2002-10-03 Rifat Pamukcu Method of inhibiting neoplastic cells with indole derivatives
JP2003513075A (ja) * 1999-11-05 2003-04-08 スミスクライン ビーチャム パブリック リミテッド カンパニー 複合５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体活性を有するイソキノリンおよびキナゾリン誘導体
WO2004108686A2 (en) * 2003-06-06 2004-12-16 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole compounds having hypoglycemic activity
WO2006057460A1 (ja) * 2004-11-29 2006-06-01 Japan Tobacco Inc. 窒素含有縮合環化合物及びその用途
WO2007097197A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. アミド誘導体またはその塩
WO2007109178A2 (en) * 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
WO2008126898A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. （アザ）インドール誘導体及びその医薬用途
WO2009129335A2 (en) * 2008-04-15 2009-10-22 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470543A1 (de) * 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung
NZ290199A (en) * 1994-07-27 1999-06-29 Sankyo Co Nitrogen containing heterocyclic compounds, selective allosteric effectors to regulate m1 receptors
AUPO118896A0 (en) * 1996-07-23 1996-08-15 Fujisawa Pharmaceutical Co., Ltd. New use
JPH10114654A (ja) * 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US7622479B2 (en) * 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
US20070197512A1 (en) 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof
EP1985297A1 (en) 2006-01-27 2008-10-29 Japan Tobacco, Inc. Carboxylic acid compound and use thereof
CA2644809A1 (en) 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
MX2009004077A (es) * 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
KR20090113326A (ko) * 2007-02-13 2009-10-29 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제
US9149463B2 (en) 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
AU2009258040B8 (en) 2008-03-13 2014-04-24 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
KR101048448B1 (ko) * 2008-11-21 2011-07-11 한국화학연구원 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05222000A (ja) * 1991-10-14 1993-08-31 Fujisawa Pharmaceut Co Ltd ベンズイミダゾール誘導体およびその製造方法
JPH10503488A (ja) * 1994-11-25 1998-03-31 三共株式会社 複素環化合物、その製造及びその治療的用途
JPH11503445A (ja) * 1995-04-10 1999-03-26 藤沢薬品工業株式会社 ｃＧＭＰ−ＰＤＥ阻害剤としてのインドール誘導体
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO1998005327A1 (en) * 1996-08-05 1998-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
WO1998015530A1 (en) * 1996-10-08 1998-04-16 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
WO1999000372A1 (fr) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfamides et leur utilisation medicale
WO1999000373A1 (en) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US20020143022A1 (en) * 1998-01-14 2002-10-03 Rifat Pamukcu Method of inhibiting neoplastic cells with indole derivatives
WO2000039099A1 (en) * 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
JP2003513075A (ja) * 1999-11-05 2003-04-08 スミスクライン ビーチャム パブリック リミテッド カンパニー 複合５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体活性を有するイソキノリンおよびキナゾリン誘導体
WO2004108686A2 (en) * 2003-06-06 2004-12-16 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole compounds having hypoglycemic activity
WO2006057460A1 (ja) * 2004-11-29 2006-06-01 Japan Tobacco Inc. 窒素含有縮合環化合物及びその用途
WO2007097197A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. アミド誘導体またはその塩
WO2007109178A2 (en) * 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
WO2008126898A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. （アザ）インドール誘導体及びその医薬用途
WO2009129335A2 (en) * 2008-04-15 2009-10-22 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016002555; ＨＵＬＭＥ，Ｃ．　ｅｔ　ａｌ: ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ Ｖｏｌ．８, 1998, ｐｐ．３０５３-３０５８ *

Also Published As

Publication number Publication date
WO2012102405A1 (ja) 2012-08-02
DK2669270T3 (en) 2018-02-26
US20140005221A1 (en) 2014-01-02
JP2017008079A (ja) 2017-01-12
JP6223514B2 (ja) 2017-11-01
JPWO2012102405A1 (ja) 2014-07-03
US20150203490A1 (en) 2015-07-23
EP2669270A4 (en) 2014-07-02
EP2669270A1 (en) 2013-12-04
US9359350B2 (en) 2016-06-07
EP2669270B1 (en) 2018-01-03
US8987473B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
JP6223514B2 (ja) 縮環化合物
JP6229020B2 (ja) ジフルオロメチレン化合物
JP6528957B2 (ja) Ｔｒｋ阻害化合物
EP2516439B1 (en) Diaza-spiro[5.5]undecanes as orexin receptor antagonists
AU757290B2 (en) Imidazolone anorectic agents: II. phenyl derivatives
US20090281120A1 (en) Bicyclic heterocyclic compound
EA035185B1 (ru) Производные спиродиамина в качестве ингибиторов альдостеронсинтазы
EP3240783B1 (en) New benzimidazole derivatives as antihistamine agents
JP2023542845A (ja) Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用
US20170022188A1 (en) Benzimidazole Derivatives and Preparation Process and Pharmaceutical Uses Thereof
DK2781508T3 (en) NITROGEN CONCENTRATED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS
JP2023547306A (ja) アリールアミド化合物、それを含む医薬組成物、その製造方法及びそれらの使用
Sharma et al. SYNTHESIS AND BIOLOGICAL ACTIVITY OF 4'-(5-AMINO-6-CHLORO-2-SUBSTITUTED-BENZOIMIDAZOL-1-YLMETHYL)]-BIPHENYL-2-CARBOXYLIC ACID AS ANTIHYPERTENSIVE AGENTS.
HK1240223A1 (en) New benzimidazole derivatives as antihistamine agents
HK1240223B (en) New benzimidazole derivatives as antihistamine agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160812

R150 Certificate of patent or registration of utility model

Ref document number: 5990106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees